|Bid||1.8700 x 1800|
|Ask||1.9800 x 800|
|Day's Range||1.8800 - 1.9800|
|52 Week Range||1.8600 - 9.5700|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.40|
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders will have a reason to smile today, with the analysts making...
– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility – – Expanding open label lead-in for SRF388 in first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2023 – – New SRF388 clinical data to be presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) --
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five new employees to purchase an aggregate of 50,000 shares of the company’s common stock with a per share exercise price of $2.33, the closing price of Surface’s common stock as reported by Nasdaq on May 2, 2022.